Laiko General Hospital of Athens

Athens, Attica 11562

5 studies enrolling now · 17 studies all time

What they study most

Acute Myeloid Leukemia (AML), Amyloidosis, Anemia, Autologous Stem Cell Transplant, Chronic Anemia, Diffuse Cutaneous Systemic Sclerosis, Follicular Lymphoma, Immunoglobulin A Nephropathy (IgAN), Ineffective Erythropoiesis, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma

Studies at this site

• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) — Recruiting now
• A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib — Recruiting now
• Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML — Recruiting now
• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) — Recruiting now
• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — Recruiting now
• A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body — Running, not enrolling
• Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors — Stopped early
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Running, not enrolling
• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma — Completed
• A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity — Running, not enrolling
• A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State — Running, not enrolling
• An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) — Stopped early
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) — Completed
• A Study of IMR-687 in Subjects With Sickle Cell Disease — Stopped early
• Ixazomib Rollover Study — Completed
• A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant — Completed
• Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia — Completed